碳酸氢钠用于重症代谢性酸中毒并休克成人患者
该实用性、适应性、双盲随机试验纳入55个ICU、7个国家的500例接受血管升压药的代谢性酸中毒成人,随机接受碳酸氢钠或5%葡萄糖安慰剂输注最多5小时,调整速率至目标pH至少7.30、碱剩余至少0 mmol/L。30天内主要不良肾脏事件(死亡、肾脏替代治疗或持续性肾功能不全)在碳酸氢钠组244例中98例(40.2%)、安慰剂组254例中100例(39.4%),校正差值1.2个百分点(95%CI -7.1至9.4;P=0.78)。30天内肾脏替代治疗使用率碳酸氢钠组16.8% vs 安慰剂组20.9%(校正差值-3.9个百分点;95%CI -10.6至2.7),30天住院死亡率25.4% vs 24.0%(校正差值1.8个百分点;95%CI -5.6至9.2)。碳酸氢钠组4例(1.6%)出现不良效应,安慰剂组无(P=0.06)。
要点
- 接受血管升压药的代谢性酸中毒成人中,碳酸氢钠组30天主要不良肾脏事件40.2% vs 安慰剂组39.4%,校正差值1.2个百分点(95%CI -7.1至9.4;P=0.78)。
- 30天内肾脏替代治疗使用率碳酸氢钠组16.8% vs 安慰剂组20.9%,校正差值-3.9个百分点(95%CI -10.6至2.7),未达统计学显著。
- 30天住院死亡率碳酸氢钠组25.4% vs 安慰剂组24.0%,校正差值1.8个百分点(95%CI -5.6至9.2)。
- 碳酸氢钠组4例(1.6%)出现不良效应,安慰剂组0例(P=0.06)。
- 入选标准为pH<7.30、碱剩余≤-4 mmol/L、未插管时动脉二氧化碳分压≤45 mm Hg或插管时≤50 mm Hg,且正在ICU接受血管升压药。
适用人群与场景
- ICU内正在接受血管升压药的成人代谢性酸中毒患者。
- 入选条件:pH<7.30;碱剩余≤-4 mmol/L;未插管时动脉二氧化碳分压≤45 mm Hg,插管时≤50 mm Hg。
诊断标准与关键阈值
- 代谢性酸中毒定义:pH<7.30、碱剩余≤-4 mmol/L、未插管时动脉二氧化碳分压≤45 mm Hg或插管时≤50 mm Hg。
- 输注目标:pH至少7.30、碱剩余至少0 mmol/L。
处置流程与药物剂量
- 碳酸氢钠或安慰剂(5%葡萄糖)输注最多5小时,输注速率按目标pH至少7.30、碱剩余至少0 mmol/L调整。
- 研究方案中碳酸氢钠组接受碳酸氢钠输注,安慰剂组接受5%葡萄糖输注,均最多5小时并按上述目标调整速率。
研究设计与关键结果
- 研究类型:实用性、适应性、双盲随机试验;样本量500例;55个ICU;7个国家;碳酸氢钠组245例、安慰剂组255例。
- 主要终点30天内主要不良肾脏事件(死亡、肾脏替代治疗或持续性肾功能不全):碳酸氢钠组244例中98例(40.2%)vs 安慰剂组254例中100例(39.4%),校正差值1.2个百分点(95%CI -7.1至9.4;P=0.78)。
- 30天内肾脏替代治疗:碳酸氢钠组16.8% vs 安慰剂组20.9%,校正差值-3.9个百分点(95%CI -10.6至2.7)。
- 30天住院死亡率:碳酸氢钠组25.4% vs 安慰剂组24.0%,校正差值1.8个百分点(95%CI -5.6至9.2)。
- 不良效应:碳酸氢钠组4例(1.6%)vs 安慰剂组0例(P=0.06)。
证据类型、等级与局限
- 证据类型:随机对照试验(实用性、适应性、双盲设计)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在ICU接受血管升压药的代谢性酸中毒成人中,碳酸氢钠较安慰剂未降低30天内主要不良肾脏事件风险,该结果不支持下述做法:仅为此终点常规使用碳酸氢钠。
- 适用人群为符合入选标准(pH<7.30、碱剩余≤-4 mmol/L、动脉二氧化碳分压条件)且正在接受血管升压药的ICU成人;不适用人群未在原文报告。
- 碳酸氢钠组4例(1.6%)出现不良效应,安慰剂组0例(P=0.06)。
指南或共识出处
- SODa-BIC试验,ClinicalTrials.gov注册号NCT05697770,由澳大利亚国家健康与医学研究委员会资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Metabolic acidosis is common in critically ill patients and is associated with organ dysfunction and death. Sodium bicarbonate is used to correct acidemia, but its benefit in patients with metabolic acidosis who are receiving vasopressors remains uncertain.
METHODS: In this pragmatic, adaptive, double-blind, randomized trial, we assigned adults with metabolic acidosis (pH, <7.30; base excess, no more than -4 mmol per liter; and partial pressure of arterial carbon dioxide, ≤45 mm Hg without intubation or ≤50 mm Hg with intubation) who were receiving vasopressors in the intensive care unit (ICU) to receive either sodium bicarbonate or placebo (5% dextrose). Sodium bicarbonate or placebo was infused for up to 5 hours, with the infusion rate adjusted for a target pH of at least 7.30 and base excess of at least 0 mmol per liter. The primary outcome was a major adverse kidney event, defined as death, use of renal-replacement therapy, or persistent renal dysfunction, within 30 days.
RESULTS: A total of 500 patients were enrolled in 55 ICUs across seven countries; 245 patients were assigned to receive sodium bicarbonate and 255 to receive placebo. A major adverse kidney event within 30 days occurred in 98 of 244 patients (40.2%) in the sodium bicarbonate group and in 100 of 254 patients (39.4%) in the placebo group (adjusted difference, 1.2 percentage points; 95% confidence interval [CI], -7.1 to 9.4; P = 0.78). Renal-replacement therapy was used within 30 days in 16.8% of the patients in the sodium bicarbonate group and in 20.9% of those in the placebo group (adjusted difference, -3.9 percentage points; 95% CI, -10.6 to 2.7). In-hospital mortality by day 30 was 25.4% in the sodium bicarbonate group and 24.0% in the placebo group (adjusted difference, 1.8 percentage points; 95% CI, -5.6 to 9.2). Four patients (1.6%) in the sodium bicarbonate group had an adverse effect, as compared with none in the placebo group (P = 0.06).
CONCLUSIONS: The use of sodium bicarbonate in critically ill patients with metabolic acidosis receiving vasopressors did not lead to a lower risk of major adverse kidney events within 30 days than placebo. (Funded by the National Health and Medical Research Council of Australia; SODa-BIC ClinicalTrials.gov number, NCT05697770.).
参考来源
- Serpa Neto A, McNamara M, White K, et al. Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock. N Engl J Med. 2026. PMID: 42283370. doi:10.1056/NEJMoa2600526
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。